News :: Matinas BioPharma Holdings, Inc. (MTNB)

Matinas in the news.

Aug 4, 2020 • 7:00 AM EDT

Matinas BioPharma to Participate in the BTIG Virtual Biotech Conference 2020

Jul 28, 2020 • 7:00 AM EDT

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2020 Financial and Operational Results on August 10, 2020

Jun 30, 2020 • 4:15 PM EDT

Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials

View all news

MAT9001: NOVEL OMEGA-3 FATTY ACID COMPOSITION

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

View

Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia

View

MAT2203: Encochleated formulation of amphotericin B

A Novel Encochleated Atovaquone Formulation is Active in a Murine Model of Pneumocystis Pneumonia

View

Efficacy of Oral Cochleate-Amphotericin B for the Prevention of Invasive Candidiasis in Neutropenic Mice

View

Oral Dosing of Encochleated Amphotericin B (CAmB): RapOral Dosing of Encochleated Amphotericin B (CAmB): Rapid Drug Targeting to Infected Tissues in Mice with Invasive Candidiasis; A-054: Mannino/Perlin: ICAAC 2015

View

Oral Administration of Amphotericin B (Oral Administration of Amphotericin B (CAmB) in Humans: a Phase I Study of Tolerability and Pharmacokinetics - Data showing results from Phase I clinical trial; Phase 1 SAD: Imedex’ “Focus on Fungal Infections” 2009**

View

Oral Administration of Amphotericin B: Toxicokinetic Studies in Animal Models - Data showing reduced toxicity of oral encochleated amphotericin B; 28-day Rat/Dog Tox: “Focus on Fungal Infections” 2009**

View

Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis; Antimicrob Agents Chemother. 2002 Aug; 46(8): 2704–2707

View

Efficacy of Oral Cochleate-Amphotericin B in a Mouse Model of Systemic Candidiasis; Antimicrob Agents Chemother. 2000 Sep; 44(9): 2356–2360

View

Antifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model; Antimicrob Agents Chemother. 2000 Jun; 44(6): 1463–1469

View

Efficacy in Mouse model of Cryptococcal Meningoencephalitis; Crypto slides: AIDS- Associated Mycoses scientific meeting, Capetown, July 2016

View

Efficacy of Oral Encochleated Amphotericin B (CAMB) in a Mouse Model of Cryptococcal Meningoencephalitis; Poster Presentation 189 ASM Microbe 2017

View

Oral Encochleated Amphotericin B (CAMB) in the Treatment of Chronic Azole Resistant Mucocutaneous Candidiasis; Poster Presentation 240 ASM Microbe 2017

View

MAT2501: Encochleated formulation of Amikacin

Oral Encochleated Amikacin Demonstrates Activity In Vitro and In Vivo In Biofilm Models of Mycobacterium avium; B-539: Lu/Mannino/ElliasBonitz/Bermudez: ICAAC 2015

View

ASTMH 2012 - Data showing the ability of cochleates to deliver aminoglycosides orally was presented at the 2012 American Society of Tropical Medicine and Hygiene conference; LB-176: Mannino/Lu/Bonitz/Bermudez: ASTMH 2012 (Am.Soc.Trop.Med.Hyg.)

View

Other Cochleate Technology Data

IDWeek 2016 Poster - Formulation of Orally and Intranasally Administered Influenza Vaccine in Cochleate Lipid-Crystal Nano-Particles Significantly Enhances Immune Response in Murine Models of Influenza; IDweek 2016 flu vaccine poster

View

Biotech 2012 Innovation Corridor - Our technology was featured at the Biotech 2012 Innovation Corridor for the demonstrated ability to orally deliver antimicrobial drugs. Our poster was selected as one of the winners by a panel of judges; Biotech 2012 Corridor: technology poster

View

Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl- s-Triazole Derivative in a Murine Model of Graft-Versus- Host Disease; Transplantation. 2008 Jul 15;86(1):171-5. doi: 10.1097/TP.0b013e31817ba761

View

Pharmacokinetics and Efficacy of Encochleated Atovaquone (CATQ) in Murine Model of Pneumocystis; IDweek 2015 Poster presentation CATQ by NIH

View

10 mg /Kg lung (outlier) Lipid-Crystal Nano-Particles: Formulation and Delivery of Oligonucleotides; CHI April 2016 Boston conference Poster on “oligonucleotides”

View

Formulation of Ibuprofen in Lipid-Crystal Nano-Particles Enhances Efficacy and Reduces Gastric Mucosal Erosions in a Rat Carrageenan-induced Paw Inflammation Model; EULAR June 2016 abstract on encochleated Ibuprofen

View

Efficacious and Commercially Viable DNA Vaccines: Plasmids Formulated into Lipid-Crystal Nano-Particles for Oral and Systemic Immunization; ECCMID April 2017 Poster on DNA plasmid vaccines

View

UPCOMING EVENTS

Aug 10 2020

Quarterly Update Conference Call and Webcast

Related Materials

Aug 11 2020

BTIG Virtual Biotech Conference 2020

Webcast Related Materials

PAST EVENTS

Jun 2 2020

Jefferies 2020 Healthcare Conference

Webcast Related Materials

May 11 2020

Quarterly Update Conference Call and Webcast

Webcast Related Materials

May 5 2020

Maxim Group Infectious Disease Virtual Conference

Related Materials

View All Events